5mg vs 10mg Vials: What's Actually Missing

A reader on r/Peptides asked a version of a question that comes up constantly: should you buy CJC-1295 and ipamorelin in 5mg vials or 10mg vials, and does a bigger vial just sit around too long once it is mixed with water^[5]? The honest answer is that vial size alone does not tell you much. 5mg and 10mg describe the total peptide mass sealed in the vial before anything is added to it, not how concentrated or 'strong' the mixed solution ends up. The number that actually matters, and the one that is missing here, is an official reconstitution and stability standard, and neither CJC-1295 nor ipamorelin has one.

Vial size is not the same thing as concentration

Mass and concentration are two different measurements. A vial labeled 5mg or 10mg tells you how much dry peptide is in the glass. Concentration only exists after that powder is dissolved in a liquid, and it depends entirely on how much liquid is used. For an approved injectable peptide, that second number is not left to the buyer. Tesamorelin, sold as Egrifta SV for HIV-associated lipodystrophy, ships as a lyophilized powder with an exact, manufacturer-tested instruction: reconstitute one vial with 0.5 mL of diluent to reach 2 mg per 0.5 mL, then use it right away^[1].

That figure was generated during Theratechnologies' approval studies and printed on an FDA-cleared label. The label also tells the patient to discard any solution and diluent left over rather than store it for later use. Nobody is guessing at that number, and nobody had to choose between a 5mg and a 10mg version, because the manufacturer already ran the study and picked one.

Why there is no label to check for CJC-1295 or ipamorelin

CJC-1295 and ipamorelin have never gone through that process. Neither has FDA marketing approval, and neither has a manufacturer-published reconstitution or stability spec, because no manufacturer has ever had to defend one to a regulator. FDA has looked at both substances directly, and not favorably. Its public list of bulk drug substances that may present significant safety risks in compounding describes ^[2] acetate as added to Category 2 of the interim compounding list on September 29, 2023, over immunogenicity risk from aggregation and peptide-related impurities, and cites a published report of serious adverse events, including a death, when ipamorelin was given intravenously.

CJC-1295 sits on the same FDA page in its withdrawn-nominations table, flagged over its own safety concerns, including immunogenicity risk and reports of increased heart rate and a systemic vasodilatory reaction, with the agency describing available clinical data as limited^[2]. FDA's Pharmacy Compounding Advisory Committee also took up ipamorelin's eligibility for the 503A bulks list directly, reviewing both ipamorelin acetate and ipamorelin free base at its October 29, 2024 meeting^[3]. No FDA approval, no cleared compounding pathway, and no manufacturer on record means there is nobody whose job it is to publish a validated dilution volume or a tested shelf life for either peptide.

What actually happens once a peptide is in solution

General peptide chemistry explains why manufacturers bother testing this at all. A 2023 review of protein and peptide instability in ^[4] describes lyophilized (freeze-dried) peptide powder as chemically far more stable than the same peptide once it is dissolved. Once water is added, four degradation pathways start running at the same time: hydrolysis breaks the peptide backbone, oxidation attacks certain amino acids, deamidation converts asparagine and glutamine residues into different molecules, and aggregation clumps peptide chains together. Temperature and time both speed all four processes up.

That is the real reason Egrifta SV's label tells patients to inject immediately after mixing and throw away whatever is left over^[1], rather than store the reconstituted vial for a week. It is a specific answer to a specific, tested formulation. It does not transfer to a different peptide, a different diluent volume, or a different vial size, and nobody has published the equivalent study for CJC-1295 or ipamorelin.

What we don't yet know

We do not know a validated shelf life for reconstituted CJC-1295 or ipamorelin, because no controlled study answering that question has been published. We do not know a safe or effective diluent volume for either peptide, because neither has completed the kind of trial program that would establish one. This article is not a reconstitution guide, and it does not recommend a vial size, a mixing ratio, or a supplier. Anyone presenting a specific mg-per-mL number or a specific shelf life for either peptide with confidence is going beyond what has actually been studied and published.

Why this matters

The 5mg-versus-10mg question treats vial size like a value comparison between two sizes of the same approved product, but there is no approved product here to compare against. CJC-1295 and ipamorelin circulate as unauthorized research-use peptides with no marketing approval anywhere and, per FDA's own bulk drug substance review, no cleared pathway into a licensed pharmacy's compounding supply^[2]. If you are weighing whether to use either peptide at all, that is a conversation for a clinician who knows your health history and can weigh the gaps directly, not something a vial-size preference settles. See the ipamorelin regulation section for the current status in your country.